Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Startup Forty Seven Inc Completes $75M Series B Financing

By Forty Seven Inc | October 20, 2017

Forty Seven Inc., a clinical-stage company developing the next generation of immuno-oncology treatments, announced the completion of a $75 million Series B financing.

The funds will be used to support continued development of Hu5F9-G4, an antibody against CD47, which takes the brakes off macrophages in a similar way as checkpoint inhibitors take the brakes off T-cells. The company is already evaluating Hu5F9-G4 in five ongoing monotherapy Phase 1b and combination therapy Phase 1b/2 trials, in patients with solid tumors, leukemia or lymphoma. These trials will be expanded and new trials commenced combining Hu5F9-G4 with T-cell checkpoint inhibitors. Forty Seven believes targeting the CD47/SIRP-alpha pathway provides a unique platform to harness the power of the patient’s immune system to defeat their cancer.

The financing was led by new investor Wellington Management Company LLP with participation from existing investors Clarus, Lightspeed Venture Partners, Sutter Hill Ventures and GV (Google Ventures).

“Forty Seven continues to make tremendous progress across multiple clinical trials,” said CEO Mark McCamish. “The financing allows us to rigorously explore the clinical response of different tumors to Hu5F9-G4 mono- and combination therapy and determine the optimal pathway to rapidly bring this new treatment option to patients.”

Dr. Dennis Henner, Board member and Managing Director at Clarus said “Forty Seven’s Hu5F9-G4 is a first-in-class CD47 antagonist that, based on strong science, preclinical and emerging clinical data, has potential applications in many different tumor types as a monotherapy or in combination therapy with tumor-targeting antibodies and potentially with other immuno-oncology agents. With this new financing, the company will be able to generate clinical data in multiple settings and will be well positioned to initiate registration trials.”

Related Articles Read More >

New nanopore sensor paves the way for fast, accurate, low-cost DNA sequencing
E. coli makes Tylenol from plastic waste
2025 R&D layoffs tracker hits 132,075 as Amazon CEO signals AI will cut more jobs
Probiotics power a bioresorbable battery that can run from 4 to 100+ minutes
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE